A Phase 3 interventional study of VX-661 plus ivacaftor combination and Ivacaftor in Cystic Fibrosis, sponsored by Vertex Pharmaceuticals Incorporated. Completed at 43 sites in 7 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2018-06-12.
Sponsored by Vertex Pharmaceuticals Incorporated · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 43 studies testing tezacaftor in Cystic Fibrosis — 4 open to participants now, 7 under way, 2 of them phase 3. tezacaftor · Cystic Fibrosis.
Among the 43 studies testing tezacaftor in Cystic Fibrosis, this one is the 12th largest by enrollment, is one of 5 that started in 2015, is one of 25 in phase 3, and was the 8th registered.
1,621 studies on the registry are indexed under Cystic Fibrosis; 201 are open to participants now.
Browse Cystic Fibrosis studies →4 of the 43 studies testing tezacaftor in Cystic Fibrosis are open now, in 2 countries. Recruiting first, the newest first:
Istituto Giannina Gaslini · Sites in Italy
Ages 6+
Vertex Pharmaceuticals Incorporated · Sites in United States
Ages 18–55 · Healthy volunteers
Vertex Pharmaceuticals Incorporated · Sites in United States
Ages 18–55 · Healthy volunteers
Arkansas Children's Hospital Research Institute · Sites in United States
Ages 3+
By country, each count listing its studies:
tezacaftor: first FDA approval 2024 (ALYFTREK), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →
Of the 156 Cystic Fibrosis studies recruiting now, 95 (61%) set no upper age limit and 45 (29%) stop at 75 or younger; 86 take children under 18; 41 take healthy volunteers.
This study: 12 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
43 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 10 · Phase 3 25 · Phase 4 3
First in 2012; this study’s year is marked. 5 started in 2015.
This study's enrollment of 168 is above the median of 36 across 1,053 interventional studies indexed under Cystic Fibrosis.
Median enrollment 100 across the 43 interventional studies. Of the 36 that completed or were terminated, 31 (86%) have results posted.
This tab as a report to print or save as PDF → With an account.
39 of 43 have an industry lead sponsor. The 5 most frequent:
Vertex Pharmaceuticals Incorporated is the lead sponsor of 249 studies on the registry; 17 are open to participants now.
Of its 107 completed or terminated interventional studies of FDA-regulated products, 54 (50%) have results posted.
125 studies in Cystic Fibrosis by Vertex Pharmaceuticals Incorporated: 3 open now, 8 under way, 5 of them phase 3. Of 112 finished, 80 (71%) have results posted.
Among the 125 studies in Cystic Fibrosis by Vertex Pharmaceuticals Incorporated, this one is the 30th largest by enrollment of the 116 interventional ones that give a count, is one of 12 that started in 2015, is one of 62 in phase 3, and was the 44th registered.
Vertex Pharmaceuticals Incorporated’s Cystic Fibrosis studies by the year they started, since 2007.
4 of the studies testing tezacaftor in Cystic Fibrosis that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05331183Phase 3Vertex Pharmaceuticals IncorporatedStudy to Evaluate Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) Long-term Safety and Efficacy in Subjects Without F508del | 2027-04-06 |
| NCT06460506Phase 3Vertex Pharmaceuticals IncorporatedEvaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA in Cystic Fibrosis Participants 12 Months of Age and Older | 2027-09-30 |
| NCT07437105Vertex Pharmaceuticals IncorporatedDose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-272 in Healthy Participants | 2027-06-26 |
| NCT07283770Vertex Pharmaceuticals IncorporatedEvaluation of VX-581 in Healthy Participants and in Participants With Cystic Fibrosis | 2027-07-12 |
Add all 4 to your calendar (.ics) → With an account.
Among the 43 studies testing tezacaftor in Cystic Fibrosis, from their registry updates:
Among Vertex Pharmaceuticals Incorporated’s 125 in Cystic Fibrosis:
This tab as a report to print or save as PDF → With an account.
Study to evaluate the efficacy of VX-661 in combination with ivacaftor (IVA, VX-770) through Week 12 in participants with cystic fibrosis (CF) who are heterozygous for the F508del mutation on the CF transmembrane conductance regulator (CFTR) gene and with a second CFTR mutation that is not likely to respond to VX-661 and/or IVA therapy (F508del/not responsive [NR]).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
VX-661 100 milligram (mg) plus IVA 150 mg fixed dose combination (FDC) tablet administered orally in the morning and IVA 150 mg film-coated tablet administered orally in the evening up to Week 12.
Drug: VX-661 plus ivacaftor combination · Drug: Ivacaftor
Placebo matched to VX-661 plus IVA FDC tablet administered orally in the morning and placebo matched to IVA film-coated tablet administered orally in the evening up to Week 12.
Drug: Placebo (matched to VX-661 plus ivacaftor combination) · Drug: Placebo (matched to ivacaftor)
Drug pages: Tezacaftor · Ivacaftor
Also known as: IVA, VX-770
Absolute Change From Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (FEV1) Through Week 12
FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration. Hankinson and Wang standards were used to calculate percent predicted FEV1 (for age, gender, and height). The Hankinson standard was used for male participants 18 years and older and female participants 16 years and older. The Wang standard was used for male participants aged 12 to 17 years and for female participants aged 12 to 15 years.
Time frame: Baseline, Through Week 12
Absolute Change From Baseline in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain Score Through Week 12
The CFQ-R is a validated participant-reported outcome measuring health-related quality of life for participants with cystic fibrosis. Respiratory domain assessed respiratory symptoms (for example, coughing, congestion, wheezing), score range: 0-100; higher scores indicating fewer symptoms and better health-related quality of life.
Time frame: Baseline, Through Week 12
Number of Pulmonary Exacerbation Events
Pulmonary exacerbation was defined as the treatment with new or changed antibiotic therapy (intravenous, inhaled, or oral) for greater than or equal to 4 sinopulmonary signs/symptoms. The number of events were reported.
Time frame: Baseline through Week 12
Number of Pulmonary Exacerbation Events Per Year
Pulmonary exacerbation was defined as the treatment with new or changed antibiotic therapy (intravenous, inhaled, or oral) for greater than or equal to 4 sinopulmonary signs/symptoms. Total number of days on study is equal to the Week 12 date or the last dose date (whichever occurs last) minus first dose date plus 1. The total number of years (48 weeks) on study is equal to the total number of days on study divided by 336. Pulmonary exacerbation events per year (48 weeks) are reported.
Time frame: Baseline through Week 12
Absolute Change From Baseline in Body Mass Index (BMI) at Week 12
BMI was defined as weight in kilogram (kg) divided by height\*height in square meter (m\^2).
Time frame: Baseline, Week 12
Relative Change From Baseline in Percent Predicted FEV1 Through Week 12
FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration. Hankinson and Wang standards were used to calculate percent predicted FEV1 (for age, gender, and height). The Hankinson standard was used for male participants 18 years and older and female participants 16 years and older. The Wang standard was used for male participants aged 12 to 17 years and for female participants aged 12 to 15 years.
Time frame: Baseline, Through Week 12
Absolute Change From Baseline in Sweat Chloride Through Week 12
Sweat samples were collected using an approved collection device.
Time frame: Baseline, Through Week 12
Number of Participants With at Least One Pulmonary Exacerbation Through Week 12
Pulmonary exacerbation was defined as the treatment with new or changed antibiotic therapy (intravenous, inhaled, or oral) for greater than or equal to 4 sinopulmonary signs/symptoms. Time-to-first pulmonary exacerbation was planned to be estimated using Kaplan-Meier (KM) estimates. However, due to less than 50% of events, time-to-first event data was not estimated. Instead, number of participants with at least one pulmonary exacerbation event were collected and are reported.
Time frame: Baseline through Week 12
Absolute Change From Baseline in BMI Z-score at Week 12 (in Participants Less Than [<] 20 Years Old at the Time of Screening)
Z-score is a statistical measure to evaluate how a single data point compares to a standard. It describes whether a mean was above or below the standard and how unusual the measurement is, with range from infinity to +infinity; where 0: same mean, \>0: a greater mean, and \<0: a lesser mean than the standard. BMI, adjusted for age and sex, was analyzed as BMI-for-age Z-score (BMI z-score). BMI-for-age z-score was calculated by using centers for disease control and prevention (CDC) growth charts for the paediatric population.
Time frame: Baseline, Week 12
Absolute Change From Baseline in Body Weight at Week 12
Time frame: Baseline, Week 12
Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
AE: any untoward medical occurrence in a participant during the study; the event does not necessarily have a causal relationship with the treatment. This includes any newly occurring event or previous condition that has increased in severity or frequency after the informed consent form is signed. AE includes serious as well as non-serious AEs. SAE (subset of AE): medical event or condition, which falls into any of the following categories, regardless of its relationship to the study drug: death, life threatening adverse experience, inpatient hospitalization/prolongation of hospitalization, persistent/significant disability or incapacity, congenital anomaly/birth defect, important medical event. Any AE that increased in severity or newly developed at or after initial dosing of study drug to Week 16 was considered treatment-emergent.
Time frame: Baseline up to Week 16
Trough Plasma Concentrations (Ctrough) of VX-661, VX-661 Metabolite (M1 VX-661), Ivacaftor (IVA) and IVA Metabolite (M1-IVA)
This outcome was not planned to be assessed in Placebo arm.
Time frame: Pre-morning dose on Week 2, Week 4, Week 8 and Week 12
The study was conducted across 38 sites in 7 countries.
| Milestone | Placebo | VX-661/IVA |
|---|---|---|
| Started | 85 | 83 |
| Completed | 85 | 81 |
| Not completed | 0 | 2 |
| Withdrew: Adverse event | 0 | 1 |
| Withdrew: Withdrawal by subject | 0 | 1 |
FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration. Hankinson and Wang standards were used to calculate percent predicted FEV1 (for age, gender, and height). The Hankinson standard was used for male participants 18 years and older and female participants 16 years and older. The Wang standard was used for male participants aged 12 to 17 years and for female participants aged 12 to 15 years.
| Percentage of predicted FEV1 | Placebo | VX-661/IVA |
|---|---|---|
| Absolute Change From Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (FEV1) Through Week 12 | -0.1 ± 0.6 | 1 ± 0.6 |
The CFQ-R is a validated participant-reported outcome measuring health-related quality of life for participants with cystic fibrosis. Respiratory domain assessed respiratory symptoms (for example, coughing, congestion, wheezing), score range: 0-100; higher scores indicating fewer symptoms and better health-related quality of life.
| Units on a scale | Placebo | VX-661/IVA |
|---|---|---|
| Absolute Change From Baseline in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain Score Through Week 12 | 3.8 (1.1 to 6.4) | 5.9 (3.2 to 8.5) |
Pulmonary exacerbation was defined as the treatment with new or changed antibiotic therapy (intravenous, inhaled, or oral) for greater than or equal to 4 sinopulmonary signs/symptoms. The number of events were reported.
| Pulmonary exacerbation events | Placebo | VX-661/IVA |
|---|---|---|
| Number of Pulmonary Exacerbation Events | 23 | 22 |
Pulmonary exacerbation was defined as the treatment with new or changed antibiotic therapy (intravenous, inhaled, or oral) for greater than or equal to 4 sinopulmonary signs/symptoms. Total number of days on study is equal to the Week 12 date or the last dose date (whichever occurs last) minus first dose date plus 1. The total number of years (48 weeks) on study is equal to the total number of days on study divided by 336. Pulmonary exacerbation events per year (48 weeks) are reported.
| Pulmonary exacerbation events per year | Placebo | VX-661/IVA |
|---|---|---|
| Number of Pulmonary Exacerbation Events Per Year | 0.98 | 0.97 |
BMI was defined as weight in kilogram (kg) divided by height\*height in square meter (m\^2).
| Kg/m^2 | Placebo | VX-661/IVA |
|---|---|---|
| Absolute Change From Baseline in Body Mass Index (BMI) at Week 12 | 0.22 (0.07 to 0.36) | 0.14 (-0.01 to 0.28) |
FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration. Hankinson and Wang standards were used to calculate percent predicted FEV1 (for age, gender, and height). The Hankinson standard was used for male participants 18 years and older and female participants 16 years and older. The Wang standard was used for male participants aged 12 to 17 years and for female participants aged 12 to 15 years.
| Percent Change | Placebo | VX-661/IVA |
|---|---|---|
| Relative Change From Baseline in Percent Predicted FEV1 Through Week 12 | 0.1 (-2.1 to 2.3) | 2.1 (-0.1 to 4.3) |
Sweat samples were collected using an approved collection device.
| Millimole per liter (mmol/L) | Placebo | VX-661/IVA |
|---|---|---|
| Absolute Change From Baseline in Sweat Chloride Through Week 12 | -1.2 (-3.1 to 0.7) | -4.7 (-6.6 to -2.8) |
Pulmonary exacerbation was defined as the treatment with new or changed antibiotic therapy (intravenous, inhaled, or oral) for greater than or equal to 4 sinopulmonary signs/symptoms. Time-to-first pulmonary exacerbation was planned to be estimated using Kaplan-Meier (KM) estimates. However, due to less than 50% of events, time-to-first event data was not estimated. Instead, number of participants with at least one pulmonary exacerbation event were collected and are reported.
| Participants | Placebo | VX-661/IVA |
|---|---|---|
| Number of Participants With at Least One Pulmonary Exacerbation Through Week 12 | 21 | 19 |
Z-score is a statistical measure to evaluate how a single data point compares to a standard. It describes whether a mean was above or below the standard and how unusual the measurement is, with range from infinity to +infinity; where 0: same mean, \>0: a greater mean, and \<0: a lesser mean than the standard. BMI, adjusted for age and sex, was analyzed as BMI-for-age Z-score (BMI z-score). BMI-for-age z-score was calculated by using centers for disease control and prevention (CDC) growth charts for the paediatric population.
| Z-score | Placebo | VX-661/IVA |
|---|---|---|
| Absolute Change From Baseline in BMI Z-score at Week 12 (in Participants Less Than [<] 20 Years Old at the Time of Screening) | 0.07 (-0.05 to 0.19) | 0.02 (-0.09 to 0.13) |
| Kilograms (kg) | Placebo | VX-661/IVA |
|---|---|---|
| Absolute Change From Baseline in Body Weight at Week 12 | 0.7 (0.3 to 1.1) | 0.6 (0.2 to 1.0) |
AE: any untoward medical occurrence in a participant during the study; the event does not necessarily have a causal relationship with the treatment. This includes any newly occurring event or previous condition that has increased in severity or frequency after the informed consent form is signed. AE includes serious as well as non-serious AEs. SAE (subset of AE): medical event or condition, which falls into any of the following categories, regardless of its relationship to the study drug: death, life threatening adverse experience, inpatient hospitalization/prolongation of hospitalization, persistent/significant disability or incapacity, congenital anomaly/birth defect, important medical event. Any AE that increased in severity or newly developed at or after initial dosing of study drug to Week 16 was considered treatment-emergent.
| Participants | Placebo | VX-661/IVA |
|---|---|---|
| Participants with any AEs | 68 | 64 |
| Participants with any SAEs | 14 | 11 |
This outcome was not planned to be assessed in Placebo arm.
| nanogram per milliliter (ng/mL) | VX-661/IVA |
|---|---|
| Week 2: VX-661 | 1880 ± 1230 |
| Week 2: M1 VX-661 | 4600 ± 1430 |
| Week 2: IVA | 831 ± 607 |
| Week 2: M1-IVA | 1580 ± 879 |
| Week 4: VX-661 | 1780 ± 1010 |
| Week 4: M1 VX-661 | 4420 ± 1340 |
| Week 4: IVA | 770 ± 596 |
| Week 4: M1-IVA | 1500 ± 898 |
| Week 8: VX-661 | 1920 ± 2170 |
| Week 8: M1 VX-661 | 4330 ± 1980 |
| Week 8: IVA | 747 ± 745 |
| Week 8: M1-IVA | 1370 ± 1070 |
| Week 12: VX-661 | 1700 ± 1220 |
| Week 12: M1 VX-661 | 4290 ± 1730 |
| Week 12: IVA | 776 ± 690 |
| Week 12: M1-IVA | 1620 ± 1160 |
Collected over Baseline up to Week 16. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 0/85 (0%) | 14/85 (16.5%) | 63/85 (74.1%) |
| VX-661/IVA | 0/83 (0%) | 11/83 (13.3%) | 62/83 (74.7%) |
| Event | Placebo | VX-661/IVA |
|---|---|---|
| Infective pulmonary exacerbation of cystic fibrosisInfections and infestations | 12/85 | 6/83 |
| Distal intestinal obstruction syndromeGastrointestinal disorders | 0/85 | 3/83 |
| HaemoptysisRespiratory, thoracic and mediastinal disorders | 1/85 | 2/83 |
| Adenocarcinoma of colonNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/85 | 1/83 |
| Lower respiratory tract infection bacterialInfections and infestations | 0/85 | 1/83 |
| Pulmonary function test decreasedInvestigations | 1/85 | 0/83 |
| Productive coughRespiratory, thoracic and mediastinal disorders | 1/85 | 0/83 |
| InfluenzaInfections and infestations | 1/85 | 0/83 |
| SinusitisInfections and infestations | 1/85 | 0/83 |
| Event | Placebo | VX-661/IVA |
|---|---|---|
| CoughRespiratory, thoracic and mediastinal disorders | 27/85 | 19/83 |
| Infective pulmonary exacerbation of cystic fibrosisInfections and infestations | 15/85 | 17/83 |
| Sputum increasedRespiratory, thoracic and mediastinal disorders | 12/85 | 7/83 |
| FatigueGeneral disorders | 4/85 | 10/83 |
| HaemoptysisRespiratory, thoracic and mediastinal disorders | 6/85 | 8/83 |
| Nasal congestionRespiratory, thoracic and mediastinal disorders | 8/85 | 7/83 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 7/85 | 5/83 |
| HeadacheNervous system disorders | 7/85 | 5/83 |
| NauseaGastrointestinal disorders | 6/85 | 6/83 |
| Oropharyngeal painRespiratory, thoracic and mediastinal disorders | 6/85 | 5/83 |
| Age, Continuous(years) | Placebo | VX-661/IVA | Total |
|---|---|---|---|
| Mean | 26 ± 8.8 | 26.2 ± 9.6 | 26.1 ± 9.2 |
| Sex: Female, Male(Participants) | Placebo | VX-661/IVA | Total |
|---|---|---|---|
| Female | 42 | 39 | 81 |
| Male | 43 | 44 | 87 |
The record gives a start of Aug 2015, a primary completion of Jun 2016 and a completion of Jun 2016. It does not say whether these dates are actual or estimated.
Results were first posted in Jun 2018, 2 years after primary completion. A results delay was requested in Jun 2017.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Tezacaftor · Ivacaftor
Vertex Pharmaceuticals Incorporated →